CD4 and neoplasm: Growth of subcutaneous CMS5a tumours (1.0–1.2 cm tumour diameter) was significantly attenuated in DUC18 CD8 EV- and BALB CD8 EV-treated groups by i.t. administration compared to BALB CD4 EV (from CD8+ cell-depleted BALB/c splenocytes)-, CMS5a EV- or hPBMC EV-treated groups (Supplementary Fig. 4a).